glp-1 hfpef Impact of receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis | Clinical Research in Cardiology Superior cardiovascular protection with GLP-1

Yes, clinical evidence supports safe concurrent use of GLP-1 agonists and TRT in most men without direct pharmacological conflict

The FDA required a black box warning on the drugs label due to the risk of thyroid tumors in animal studies, and this warning continues to shape how the drug is prescribed and monitored

After screening titles and abstracts and conducting full-text reviews, the number of studies considered for this meta-analysis was reduced to 30

Whats brought you here

Two authors assessed the risk of bias for each study through five aspects: random sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting

What is it, why is it used, and why is it discussed in the same breath as hGH